CRMD · Biotech · Nasdaq · As of 21 Nov 2026
CorMedix Inc. stock: filings, catalysts and timeline
Sign in to follow
AIR Score
Cautious · 49 / 100
AIR confidence
Support behind the full AIR read.
What is this? →Hide
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
The Discovery Gap
Very high
Gap confidence
How fully AIR could measure this Gap — separate from the AIR Score's confidence.
What is this? →Hide
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Five perspectives
FundamentalsWhat is this?HideToo few of the required measures on file
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HideVery strong
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideWeak
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideBalanced
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Rating words, not raw numbers.
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on News flow, Momentum and Safety, and the missing score lowers its AIR confidence.
Discovery Gap: Very high (85/100) · Gap confidence 67/100
Discovery gap
Documented progress is running well ahead of market attention.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
This month at a glance
Evidence timeline
- Expected
Fri 5 Mar · expected 10-K
Last year filed 5 Mar 2026.
Fri 14 May · expected 10-Q
Last year filed 14 May 2026.
- Filed
Mon 16 Nov · 8-K
Thu 12 Nov · 8-K
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $54.5M beat consensus ($51.2M). Announced definitive agreement to acquire Heron Therapeutics assets (expected $125–150M annual revenue contribution in 2027, immediately accretive). FDA granted Priority Review for REZZAYO sNDA (PDUFA Q1 2027). Secured $150M term loan facility.
News flow: Balanced 52 → Balanced 56Recognition: Balanced 46 → Watch 43Gap Very high · 48 → Very high · 87The filings read more positively.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Thu 12 Nov · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2026
News flow: Balanced 52 → Balanced 56Recognition: Balanced 46 → Watch 43Gap Very high · 48 → Very high · 87The filings read more positively.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Tue 10 Nov · 8-K
News flow: Balanced 52 → Balanced 55Recognition: Balanced 46 → Watch 43Gap Very high · 49 → Very high · 84The filings read more positively.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Mon 9 Nov · 8-K
8-K · Items 1.01, 2.03, 3.02 — Material agreement
CorMedix agreed to acquire substantially all assets of Heron Therapeutics for $145M cash, 14.6M shares, royalties, and earn-out payments up to $55M. Acquisition includes marketed products CINVANTI, SUSTOL, and ZYNRELEF, expanding CorMedix's commercial portfolio.
News flow: Balanced 52 → Balanced 55Gap Very high · 49 → Very high · 82The filings read more positively.
Progress is running ahead of attention.
Mon 2 Nov · 8-K
8-K · Item 2.02 — Results of operations
CMS approved DefenCath 2027 Q1 Add-on of $8.32/session (3-5x higher than current $2.37). Company reaffirms 2026 revenue guidance of $325-345M and reports $355M cash. Full-year 2027 Add-on expected to average >2x current rate.
Gap High · 42 → Very high · 50Progress is running ahead of attention.
Mon 19 Oct · 8-K
Thu 13 Aug · 10-Q
Quarterly report (10-Q), period ending 30 Jun 2026
Thu 13 Aug · 8-K
Fri 7 Aug · 8-K
Thu 2 Jul · 8-K
Wed 1 Jul · 8-K
Wed 24 Jun · 8-K
Mon 8 Jun · 8-K
Thu 14 May · 8-K
Thu 14 May · 10-Q
Quarterly report (10-Q), period ending 31 Mar 2026
Mon 27 Apr · 8-K
Fri 6 Mar · 8-K
Thu 5 Mar · 10-K
Annual report (10-K), FY2025
Thu 5 Mar · 8-K
Thu 8 Jan · 8-K
Wed 12 Nov · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2025
Wed 12 Nov · 8-K
Mon 20 Oct · 8-K
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.